NCT01536015终止3 期
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- UCB Pharma
- 入组人数
- 25
- 试验地点
- 26
- 主要终点
- Change in Rotigotine Versus Placebo in the Absolute Time Spent "Off" From Baseline to the End of the 7-week Maintenance Period
研究概览
简要总结
The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with symptoms of Gastrointestinal Dysfunction. Hypothesis: Rotigotine will decrease OFF time compared to Placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is informed and given ample time and opportunity to think about his/her participation in this study and has given his/her written informed consent on an Institutional Review Board approved consent form
- •Subject is willing and able to comply with all study requirements (protocol, visit schedule, procedures, and medication application)
- •Subject is male or female and ≥ 30 years of age
- •Subject has Idiopathic Parkinson's Disease of more than 3 years duration, as defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes; and is without any other known or suspected cause of Parkinsonism
- •Subject has a Hoehn & Yahr stage score II through IV
- •Subject must be on a stable dose of L-dopa, either short-acting or sustained release (in combination with Benserazide or Carbidopa), of at least 200 mg/day administered in at least 2 intakes, for at least 21 days prior to starting Parkinson's diaries
- •Subject must be able to differentiate between the "on" and "off" state (and thereby be able to recognize the Time To "On" (TTON)), and be willing and able to accurately complete a Parkinson's Disease subject diary on designated days (with assistance from caregivers, if required)
- •Subject must complete 6 Parkinson's diaries over a period of 6 days, with 4 of the 6 Parkinson's diaries being "valid" as determined by the investigator. The "valid" Parkinson's diaries confirm that the subject has an average of at least 2.5 h/day spent in the "off" state
- •Subject receiving a Monoamine Oxidase (MAO)-B Inhibitor (eg, Selegiline or Rasagiline), an n-Methyl-d-Aspartate Antagonist (eg, Amantadine), or allowed anti-Parkinson medications and has been on a stable dose for at least 21 days prior to starting Parkinson's diaries and is anticipated to be maintained on that dose for the duration of the study
- •Subject has clinical symptoms of Gastrointestinal Dysfunction (GID) confirmed by at least 1 of the following
- •Parkinson's disease-related GI symptoms as per the Gastrointestinal Degenerative Scale (GIND) Scale: defecatory dysfunction, constipation, excessive gas, abdominal pain, bloating, nausea, vomiting, anorexia, early satiety, or weight loss (except sialorrhea and dysphagia)
- •Female subjects of childbearing potential must agree to use 1 of the following contraceptive methods: oral contraceptive, intrauterine device, or double-barrier method, throughout the study and for 2 weeks after the removal of study medication
排除标准
- •Subject has previously participated in this study
- •Subject has participated in another study of an investigational medicinal product (IMP) or a medical device within the last 30 days or is currently participating in another study of an IMP or a medical device
- •Subject has an Atypical Parkinsonian Syndrome due to drugs (eg, Metoclopramide, Flunarizine), Metabolic Neurogenetic Disorders (eg, Wilson's Disease), Encephalitis, Cerebrovascular Disease, or Degenerative Disease (eg, Progressive Supranuclear Palsy)
- •Subject has a history of Pallidotomy, Thalamotomy, Deep Brain Stimulation, or Fetal Tissue Transplant
- •Subject has Dementia, Active Psychosis, or Hallucinations
- •Subject exhibits Dopaminergic Dysregulation Syndrome
- •Subject is receiving therapy with certain medications in a specific timeframe as specified in the protocol
- •Subject has history of chronic Gastrointestinal (GI) Disease not related to Parkinson's disease which in the judgement of the investigator may affect the ability of the subject to participate in the study (ie, Irritable Bowel Syndrome, Diverticulitis, Crohn's Disease, etc) or GI/abdominal surgery (except for Appendectomy, Hysterectomy, or Cholecystectomy)
- •Subject has had any GI surgery in the 3 months prior to the Screening Visit
- •Subject has a current diagnosis of Epilepsy, has a history of seizures as an adult, or has a history of stroke or Transient Ischemic Attack within 1 year prior to the Screening Visit
- •Subject has clinically relevant Hepatic or Renal Dysfunction
- •Subject has clinically relevant Cardiac Dysfunction (any cardiac disorder that in the opinion of the investigator would put the subject at risk of clinically relevant arrhythmia)
- •Subject has had a Myocardial Infarction within the last 1 year prior to the Screening Visit
- •Subject has a history of Symptomatic (not Asymptomatic) Orthostatic Hypotension
- •Subject has a Systolic Blood Pressure (BP) < 105 mmHg at the Screening Visit
- •Subject has a history of chronic alcohol or drug abuse within the prior 6 months
- •Female subject is pregnant or lactating
- •Subject (male or female) is of child bearing potential but not surgically sterile or not using adequate birth control methods
- •Subject has evidence of an Impulse Control Disorder according to the Modified Minnesota Impulsive Disorders Interview (mMIDI) at the Screening Visit
- •Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the Screening Visit
- •Subject has a significant skin disease/condition that would make transdermal drug use inappropriate, including a history of skin sensitivity to adhesives or other transdermal medications
- •Subject has a known hypersensitivity to any components of the Rotigotine patch, including Sodium Metabisulfite
- •Subject has any medical, psychiatric, or cognitive condition, or laboratory abnormality that would, in the opinion of the investigator, jeopardize or compromise the subject's well-being or ability to participate in the study
研究组 & 干预措施
Rotigotine
Experimental
Rotigotine patch titrated from 4 mg/24 h - 8 mg/24 h or until effective or maximum dose is reached.
干预措施: Rotigotine (Drug)
Placebo
Placebo Comparator
Placebo patch.
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Rotigotine Versus Placebo in the Absolute Time Spent "Off" From Baseline to the End of the 7-week Maintenance Period
时间窗: Baseline to 10 weeks
Mean number of hours marked "off" during a 24-hour period.
次要结局
- Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part III (Motor Examination) in the "on" State From Baseline to the End of the 7-week Maintenance Period(Baseline to 10 weeks)
- Change in Predictability of "Off" Time (Using MDS UPDRS Part IV Item 4.5) From Baseline to End of the 7-week Maintenance Period(Baseline to 10 weeks)
- Change in Score on Gastrointestinal Neurodegenerative Scale (GIND) From Baseline to the End of the of the 7-week Maintenance Period(Baseline to 10 weeks)
- Change in Score on Fatigue Severity Scale (FSS) From Baseline to the End of 7-week Maintenance Period(Baseline to 10 weeks)
- Change in Score on Parkinson's Disease Questionnaire (PDQ8) From Baseline to the End of 7-week Maintenance Period(Baseline to 10 weeks)
研究者
研究点 (26)
Loading locations...
相似试验
已完成
4 期
Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor SymptomsIdiopathic Parkinson's DiseaseNCT01300819UCB Pharma349
已完成
4 期
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated PainAdvanced Idiopathic Parkinson's DiseaseNCT01744496UCB BIOSCIENCES GmbH68
已完成
3 期
A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs SyndromeRestless Legs SyndromeNCT00275236UCB Pharma60
已完成
4 期
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And ApathyIdiopathic Parkinson's DiseaseNCT01782222UCB BIOSCIENCES GmbH122
已完成
3 期
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal PatchParkinson's DiseaseNCT00522379UCB Pharma514